Spray freeze-drying is a two-step, semicontinuous drying process that combines spray freezing of a drug substance with dynamic bulk lyophilization to produce a free-flowing powder, and a technical evaluation published by BioProcess International on 14 December 2018 reported that the approach yielded homogeneous monoclonal antibody powder with drying times of 24–30 hours, process yields above 97% and residual moisture below 1%. The evaluation, conducted on laboratory- and pilot-scale equipment designed and manufactured by Meridion Technologies GmbH of Müllheim, Germany, used a monoclonal antibody as model drug substance and framed bulk-powder manufacturing as a route to supply-chain and drug-product flexibility for biologics.
The findings matter to the peptide therapy and research peptide sector because the same cold-chain economics and container-filling constraints that shape monoclonal antibody logistics also shape how lyophilized peptide vials, dual-chamber cartridges and prefilled injection pens move from API manufacturers to clinics, telehealth operators and research suppliers. If bulk-powder drug substance can be dried faster and filled across multiple presentations from a single batch, the downstream implications for fill-finish capacity, cold-chain dependence and clinic-level inventory planning are substantial — though the published evaluation stops well short of demonstrating commercial-scale performance or long-term room-temperature stability.
What the spray freeze-drying evaluation actually reported
According to the BioProcess International technical article, the process works in two stages. Low-shear nozzles with an orifice range of 250–1,000 µm form droplets that are flash-frozen in a liquid-nitrogen cooling tower held below –110 °C; the frozen particles then undergo freeze-drying under vacuum in a temperature-controlled rotary dryer with gentle mixing and infrared heating. Three 300-µm nozzles were used in the reported runs.
For monoclonal antibody formulations at 50, 100, 150 and 200 g/L (viscosity 2–27 cP), spray rates reached 1.0–1.2 kg/h per nozzle with no significant throughput loss at the highest viscosity. Drying took 24–30 hours for formulations at 10–36% w/w solids. Shear-cell testing classified the resulting powder as free flowing to easy flowing, and laser-light scattering showed narrow, reproducible particle-size distributions with virtually no fines below 10 µm. Sphere size was controllable through nozzle orifice selection (300 µm versus 400 µm), and scanning electron microscopy confirmed spherical particles.
The authors attribute the faster drying relative to conventional freeze-drying to constant particle motion and full particle-surface availability for heat and mass transfer. The article also cites conventional freeze drying’s batch processing, low processing efficiency and container-to-container variability, and notes that typical spray drying can yield fine powders with a mean particle size below 10 µm — suited to inhalation delivery but challenging to fill-finish into single-dose units for parenteral delivery.
| Parameter | Reported result | Evidence status |
|---|---|---|
| Model molecule | Monoclonal antibody (drug substance) | Reported in article |
| Equipment | Meridion Technologies GmbH lab/pilot rotary dryers | Reported in article |
| Formulation concentration | 50, 100, 150, 200 g/L (2–27 cP) | Authors’ own experiments |
| Spray rate | 1.0–1.2 kg/h per nozzle | Authors’ own experiments |
| Drying time | 24–30 hours | Authors’ own experiments |
| Process yield | >97% | Authors’ own experiments |
| Residual moisture | <1% | Authors’ own experiments |
| Powder flow | Free flowing to easy flowing | Shear-cell testing |
| Production-scale data | Not reported | Gap in supplied text |
Why cold chain is the pressure point for peptide vials and cartridges
Biopharmaceutical drug substances and products are commonly stored frozen or refrigerated to maintain stability through long-term storage, handling and transportation, and temperature excursions during storage and transport can adversely affect product quality by compromising the safety and efficacy of biologic molecules. Cold-chain management requires qualified, maintained and continuously monitored storage equipment at all distribution nodes, plus insulated containers, data loggers and RFID tags for temperature-controlled transport.
Those requirements carry direct cost and complexity. Frozen material transport for high-volume products demands large quantities of dry ice or other phase-change materials on each shipment pallet, and single-use disposable bags used for frozen drug substance storage can pose rupture and leakage risks during shipping and handling. The BioProcess International article describes this cold supply chain as a challenging and expensive paradigm and a potential obstacle to building robust distribution into emerging markets and warmer climates.
For peptide therapy clinics, telehealth platforms and research peptide suppliers, the practical consequence is that lyophilized powder presentations — vials, dual-chamber cartridges and injection pens — inherit storage, handling and documentation burdens that are set well upstream of the clinic refrigerator. Peptidescm as a provider in the industry domain tracks how these upstream manufacturing and packaging decisions propagate into clinic procurement and cross-border logistics planning.
The peptide industry angle: one bulk batch, several drug-product presentations
The evaluation’s most commercially relevant claim is presented as potential rather than demonstrated: that a bulk-powder drug substance strategy could support multiple drug-product presentations from a single bulk batch and aseptic filling into vials, cartridges and dual-chambered syringes, and could enable distribution without complex cold-chain infrastructure.
That framing is familiar to peptide supply-chain specialists. A peptide API is the active pharmaceutical ingredient used in drug manufacturing, while a finished drug product combines the active ingredient with appropriate formulation, container closure, manufacturing controls, labeling and release requirements — and API quality alone does not establish finished-product quality or regulatory approval. A bulk-powder intermediate that fills consistently across vial, cartridge and pen formats would sit precisely at that API-to-finished-product boundary, where fill-finish capacity and container compatibility decisions are made.
Industry observers note that the peptide sector’s container landscape — lyophilized powder in vials, dual-chamber cartridges that keep diluent and powder separate until reconstitution, and prefilled or cartridge-based injection pens — is sensitive to particle-size distribution, flow behavior and residual moisture. The reported free-flowing character and narrow size distribution are therefore relevant to fill-finish, but the published text does not report container-specific filling trials, container-closure integrity data or compatibility testing for any peptide molecule.
What remains unproven — and why that matters for procurement
Several of the evaluation’s most attractive implications are not supported by the supplied text. Long-term room-temperature stability data are absent because the source text is truncated at the rapid reconstitution section; reconstitution performance is likewise unavailable. No comparator data are presented to substantiate superiority over conventional freeze-drying in drying time, and only laboratory- and pilot-scale dryers were used — production-scale equipment is shown in a figure, but no production-scale performance data are reported.
The work also rests on assumptions the article does not test: that a monoclonal antibody is representative of other biologics, that lab- and pilot-scale results extrapolate to production scale, and that residual moisture below 1% implies long-term stability. Readers should treat the room-temperature distribution claim as an asserted potential, not an established property.
For buyers, this is the difference between a promising process concept and a qualified supplier capability. A certificate of analysis is a batch-related document reporting specified tests, results and acceptance criteria; it does not independently establish clinical safety, efficacy, sterility for a particular use, regulatory approval or suitability for administration to humans. Any future spray freeze-dried peptide bulk powder would need the same discipline: identity, assay or content, chromatographic purity, impurity profile, water content and residual solvents, supported by validated methods rather than a single purity figure.
Where this could touch clinics, pens and cross-border logistics
If bulk-powder processing were validated at commercial scale, the most plausible near-term effects would be in fill-finish flexibility and cold-chain burden rather than in clinical performance. A drug substance that can be dried in 24–30 hours and filled into multiple container formats from one batch could ease scheduling pressure on aseptic filling lines and reduce the number of distinct bulk lots a manufacturer must hold. Lower cold-chain dependence, if achieved, would matter most on long international lanes and in markets where frozen transport is expensive or unreliable.
None of this changes the regulatory picture. Some peptide medicines have FDA-approved indications, while others are investigational, unapproved or marketed for research purposes, and approval must be checked for the specific drug product, formulation, indication and applicable regulatory pathway. Research-use labeling does not establish sterility, safety or authorization for human administration, and prescription requirements and medical supervision apply to approved peptide medicines. Process innovation in drying does not alter those categories.
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What to watch next
- Publication of the truncated sections on rapid reconstitution and long-term stability, which would test the room-temperature distribution claim.
- Production-scale drying and filling data, including container-specific runs for vials, dual-chamber cartridges and injection pens.
- Whether peptide manufacturers and CDMOs evaluate spray freeze-drying for sequences and formulations where conventional lyophilization cycles are long or aggregation-prone.
- Cold-chain and documentation requirements that clinics and telehealth operators should confirm with suppliers, including batch traceability and storage instructions specific to each material.
FAQ
What is spray freeze-drying?
It is a two-step, semicontinuous process that sprays a drug substance into droplets, flash-freezes them in a cryogenic tower and then lyophilizes the frozen particles under vacuum in a dynamic rotary dryer, producing a free-flowing bulk powder.
Did the evaluation prove room-temperature storage is possible?
No. Room-temperature distribution without a complex cold chain is presented as a potential benefit; the supplied text is truncated before long-term stability data, so that claim remains unproven.
Does this apply to peptide vials and injection pens?
The evaluation used a monoclonal antibody as model drug substance and did not test peptide molecules or specific container formats. Multiple presentations from one bulk batch — including vials, cartridges and dual-chambered syringes — are described as potential, not demonstrated.
Is spray freeze-dried powder an approved medicine?
No. The work is a technical process evaluation. Approved status depends on the specific drug product, formulation, indication and regulatory pathway, and research-use materials are not authorized for human administration.
Comments